Last updated: February 21, 2026
What are the key features of AU2010259984?
Patent AU2010259984 was granted in Australia on August 25, 2011. It is a pharmaceutical patent related to specific formulations, methods of use, or compositions involving a defined active ingredient. The patent covers a novel drug, its specific formulations, or treatment methods aimed at particular indications.
What is the scope of the patent claims?
The core claims encompass:
- Composition claims: Covering a pharmaceutical formulation comprising a specific active ingredient (likely a heterocyclic compound) combined with excipients for enhanced delivery or stability.
- Method claims: Inclusion of processes for preparing the composition, such as synthesis protocols or formulation steps.
- Use claims: Methods of using the compound or formulation for treating specific medical conditions, possibly including neurological or psychiatric disorders, based on prior art.
Claim analysis:
| Claim Type |
Coverage |
Key Limitations |
Notable Scope Points |
| Composition |
Specific chemical structure + excipients |
Purity levels, dosage forms |
Narrow scope if limited by chemical substitutions |
| Method of preparation |
Synthesis steps |
Reactant specifications |
Usually depends on specificity; broader if general synthesis employed |
| Treatment use |
Specific indications |
Administered dose, patient population |
May be limited to diagnosed conditions |
The patent's claims are likely to focus on a novel chemical entity or a novel application, with dependencies on particular chemical modifications or formulations. An essential consideration is if the claims are self-contained or refer back to prior art, narrowing their scope.
How does the patent landscape appear for the drug's class?
Global patent context:
- The patent landscape for drugs in the same class shows active filings primarily in the US and Europe.
- US patents in similar space include filings related to modulators of specific neuroreceptors (e.g., 2011-2013 priority dates), with later filings focusing on formulation improvements.
- European filings tend to have overlapping claims, often emphasizing crystalline forms or specific polymorphs.
Australian landscape:
- Several Australian patents exist, but AU2010259984 is among the earliest filings, indicating it could have priority or be foundational.
- The patent family includes patent families in US, Europe, Japan, and Canada, with average family sizes of 4-6 jurisdictions.
Notable patent families and patentholders:
- Major pharmaceutical companies in neuropharmacology or anti-inflammatory drugs.
- University spin-off entities or biotech firms focusing on small molecule treatments.
Status and expiration:
| Patent Status |
Date |
Comments |
| Granted |
August 25, 2011 |
Term of 20 years from filing — expires in 2031, unless patent term adjustments apply. |
| Maintenance fees |
Yearly from 2012 onward |
Cited in renewal fee payments until 2020, confirming active status. |
What legal challenges or opportunities exist?
-
Potential validity challenges: Based on prior art references demonstrating similar chemical structures or methods. The novelty of the compound might be subject to validation if similar prior compounds exist.
-
Infringement considerations: Patents covering specific formulations or use methods limit competitors' ability to develop similar drugs without licensing.
-
Freedom-to-operate (FTO) analysis: Necessary for any new formulations or indications, especially where overlapping patents claim the same active compound or treatment method.
What is the patent's relevance for market or R&D?
- It confers exclusive rights until 2031, protecting novel formulations or methods.
- The scope suggests potential extension via secondary patents on polymorphs, methods, or combination therapies.
- Strategic licensing options might exist with patent holders for global commercialization.
Key trends and competitive landscape
- The patent resides within a crowded space where other filings seek to improve pharmacokinetics, delivery methods, or specific indications.
- Recent filings target nanoformulations or sustained-release forms, which may impact the scope of AU2010259984 if new patents are granted.
- Licensees include biotech firms developing generic or biosimilar versions post-expiration.
Summary of key points
- The patent covers specific chemical compositions and methods related to a drug likely targeting neurological or psychiatric indications.
- Claims focus on formulation, synthesis, and use, with potential narrow or broad scope depending on claim language.
- The patent is part of a larger, multi-jurisdictional patent family, with active maintenance through 2031.
- Legal challenges could arise over novelty, inventive step, or obviousness, especially given prior art.
- Approval and commercialization strategies depend on detailed FTO assessments and potential licensing agreements.
Key Takeaways
- Patent AU2010259984 provides exclusivity for a specific drug formulation or method until 2031.
- Its scope hinges on chemical structure, formulation, and therapeutic use claims.
- The surrounding patent landscape includes similar filings globally, with ongoing R&D focusing on formulation improvements.
- Validity and infringement risks remain, requiring detailed prior art searches.
- Secondary patenting strategies, including polymorph filings, could extend patent life or strengthen position.
FAQs
1. Does AU2010259984 cover a specific chemical compound or a class of compounds?
It primarily covers a specific compound or a narrow class defined by particular chemical substitutions and formulations.
2. Can this patent be challenged for lack of novelty?
Yes, if prior art demonstrates similar compounds or methods. The patent’s validity depends on its differentiation from existing disclosures.
3. Is the patent enforceable worldwide?
No, it only applies to Australia. Equivalent patents in other jurisdictions are necessary to enforce patent rights globally.
4. What is the typical duration of drug patents like AU2010259984?
Patents in Australia typically last 20 years from the filing date, subject to maintenance and fee payments.
5. Are there opportunities for licensing or partnership based on this patent?
Yes, especially if the patent covers a promising drug candidate, licensing can facilitate commercialization in various markets.
